Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis

Abstract The prophylactic vaccines available to protect against infections by HPV are well tolerated and highly immunogenic. People with HIV have a higher risk of developing HPV infection and HPV-associated cancers due to a lower immune response, and due to viral interactions. We performed a systema...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonella Zizza, Federico Banchelli, Marcello Guido, Claudia Marotta, Francesco Di Gennaro, Walter Mazzucco, Vanna Pistotti, Roberto D’Amico
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2b5b7b5931194c2fa5814cc004b011d6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2b5b7b5931194c2fa5814cc004b011d6
record_format	dspace
spelling	oai:doaj.org-article:2b5b7b5931194c2fa5814cc004b011d62021-12-02T13:30:11ZEfficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis10.1038/s41598-021-83727-72045-2322https://doaj.org/article/2b5b7b5931194c2fa5814cc004b011d62021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83727-7https://doaj.org/toc/2045-2322Abstract The prophylactic vaccines available to protect against infections by HPV are well tolerated and highly immunogenic. People with HIV have a higher risk of developing HPV infection and HPV-associated cancers due to a lower immune response, and due to viral interactions. We performed a systematic review of RCTs to assess HPV vaccines efficacy and safety on HIV-infected people compared to placebo or no intervention in terms of seroconversion, infections, neoplasms, adverse events, CD4+ T-cell count and HIV viral load. The vaccine-group showed a seroconversion rate close to 100% for each vaccine and a significantly higher level of antibodies against HPV vaccine types, as compared to the placebo group (MD = 4333.3, 95% CI 2701.4; 5965.1 GMT EL.U./ml for HPV type 16 and MD = 1408.8, 95% CI 414.8; 2394.7 GMT EL.U./ml for HPV type 18). There were also no differences in terms of severe adverse events (RR = 0.6, 95% CI 0.2; 1.6) and no severe adverse events (RR = 0.6, 95% CI 0.9; 1.2) between vaccine and placebo groups. Secondary outcomes, such as CD4 + T-cell count and HIV viral load, did not differ between groups (MD = 14.8, 95% CI − 35.1; 64.6 cells/µl and MD = 0.0, 95% CI − 0.3; 0.3 log10 RNA copies/ml, respectively). Information on the remaining outcomes was scarce and that did not allow us to combine the data. The results support the use of the HPV vaccine in HIV-infected patients and highlight the need of further RCTs assessing the effectiveness of the HPV vaccine on infections and neoplasms.Antonella ZizzaFederico BanchelliMarcello GuidoClaudia MarottaFrancesco Di GennaroWalter MazzuccoVanna PistottiRoberto D’AmicoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Antonella Zizza Federico Banchelli Marcello Guido Claudia Marotta Francesco Di Gennaro Walter Mazzucco Vanna Pistotti Roberto D’Amico Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis
description	Abstract The prophylactic vaccines available to protect against infections by HPV are well tolerated and highly immunogenic. People with HIV have a higher risk of developing HPV infection and HPV-associated cancers due to a lower immune response, and due to viral interactions. We performed a systematic review of RCTs to assess HPV vaccines efficacy and safety on HIV-infected people compared to placebo or no intervention in terms of seroconversion, infections, neoplasms, adverse events, CD4+ T-cell count and HIV viral load. The vaccine-group showed a seroconversion rate close to 100% for each vaccine and a significantly higher level of antibodies against HPV vaccine types, as compared to the placebo group (MD = 4333.3, 95% CI 2701.4; 5965.1 GMT EL.U./ml for HPV type 16 and MD = 1408.8, 95% CI 414.8; 2394.7 GMT EL.U./ml for HPV type 18). There were also no differences in terms of severe adverse events (RR = 0.6, 95% CI 0.2; 1.6) and no severe adverse events (RR = 0.6, 95% CI 0.9; 1.2) between vaccine and placebo groups. Secondary outcomes, such as CD4 + T-cell count and HIV viral load, did not differ between groups (MD = 14.8, 95% CI − 35.1; 64.6 cells/µl and MD = 0.0, 95% CI − 0.3; 0.3 log10 RNA copies/ml, respectively). Information on the remaining outcomes was scarce and that did not allow us to combine the data. The results support the use of the HPV vaccine in HIV-infected patients and highlight the need of further RCTs assessing the effectiveness of the HPV vaccine on infections and neoplasms.
format	article
author	Antonella Zizza Federico Banchelli Marcello Guido Claudia Marotta Francesco Di Gennaro Walter Mazzucco Vanna Pistotti Roberto D’Amico
author_facet	Antonella Zizza Federico Banchelli Marcello Guido Claudia Marotta Francesco Di Gennaro Walter Mazzucco Vanna Pistotti Roberto D’Amico
author_sort	Antonella Zizza
title	Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis
title_short	Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis
title_full	Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis
title_fullStr	Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis
title_full_unstemmed	Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis
title_sort	efficacy and safety of human papillomavirus vaccination in hiv-infected patients: a systematic review and meta-analysis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2b5b7b5931194c2fa5814cc004b011d6
work_keys_str_mv	AT antonellazizza efficacyandsafetyofhumanpapillomavirusvaccinationinhivinfectedpatientsasystematicreviewandmetaanalysis AT federicobanchelli efficacyandsafetyofhumanpapillomavirusvaccinationinhivinfectedpatientsasystematicreviewandmetaanalysis AT marcelloguido efficacyandsafetyofhumanpapillomavirusvaccinationinhivinfectedpatientsasystematicreviewandmetaanalysis AT claudiamarotta efficacyandsafetyofhumanpapillomavirusvaccinationinhivinfectedpatientsasystematicreviewandmetaanalysis AT francescodigennaro efficacyandsafetyofhumanpapillomavirusvaccinationinhivinfectedpatientsasystematicreviewandmetaanalysis AT waltermazzucco efficacyandsafetyofhumanpapillomavirusvaccinationinhivinfectedpatientsasystematicreviewandmetaanalysis AT vannapistotti efficacyandsafetyofhumanpapillomavirusvaccinationinhivinfectedpatientsasystematicreviewandmetaanalysis AT robertodamico efficacyandsafetyofhumanpapillomavirusvaccinationinhivinfectedpatientsasystematicreviewandmetaanalysis
_version_	1718392964577755136

Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis

Ejemplares similares